#United States #Chicago #Crenessity #Neurocrine #Congenital Adrenal Hyperplasia

Neurocrine Biosciences Reveals Significant Progress with CRENESSITY® in Congenital Adrenal Hyperplasia

At the recent ENDO 2026 annual meeting held in Chicago, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented groundbreaking clinical findings from the first retrospective case series regarding their drug CRENESSITY® (crinecerfont). This series specifically focused on patients suffering from classic congenital adrenal hyperplasia (CAH) due to 11β-hydroxylase deficiency, a rare subtype that has not been previously explored in clinical trials involving this medication.

The 11β-hydroxylase deficiency accounts for around 5% of all classic CAH cases and is characterized by both a deficiency in cortisol and an excess of adrenal androgens. In particular, it is associated with elevated levels of adrenal steroid precursors such as 11-deoxycortisol (11-dF) and 11-deoxycorticosterone (DOC).

Improvements in Hormonal Levels

The retrospective analysis included a cohort of both pediatric and adult patients, revealing substantial improvements post-treatment with CRENESSITY. The results indicated that more than 90% of patients experienced a significant reduction in levels of 11-deoxycortisol and 11-deoxycorticosterone. Of the 15 patients evaluated, 14 were able to decrease their total glucocorticoid doses, showcasing the potential of CRENESSITY in managing CAH more efficiently.

Additionally, out of five patients who were on antihypertensive medications, two managed to either reduce or completely stop their medication, highlighting the broader health improvements gained from CRENESSITY treatment. This data marks an essential step forward in understanding and managing this complex condition, particularly since existing treatment options for 11β-hydroxylase deficiency had been limited.

Expert Perspectives

Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, commented on the challenges faced by patients with this specific form of CAH, stating, "The data we’re presenting underscore a significant gap in clinical insights concerning 11β-hydroxylase deficiency. This case series helps to illustrate how CRENESSITY could be a transformative option for these patients."

Furthermore, Dr. Kyriakie Sarafoglou, a pediatric endocrinologist from the University of Minnesota, praised the findings as vital information for clinicians, emphasizing the struggle many patients face due to elevated androgen levels and other complications associated with the condition. He noted that, although the sample size was small, the insights gathered hold meaningful implications for treatment strategies moving forward.

Commitment to Advancing Care

Neurocrine's commitment to advancing treatment for the full spectrum of classic CAH and other rare endocrine diseases was further strengthened by these findings. While CRENESSITY is already approved for use alongside glucocorticoids in general CAH patients, this case series establishes a crucial groundwork for understanding how the drug can benefit those with 11β-hydroxylase deficiency specifically.

The retrospective study demonstrated changes in hormone levels within as little as one month after initiating treatment, presenting an encouraging timeline for clinicians and patients alike. Alongside these findings, the company showcased additional studies that highlighted sustained improvements in various health aspects such as weight management and cardiometabolic outcomes among individuals using CRENESSITY.

In conclusion, the initial clinical insights gained from Neurocrine Biosciences' presentation at ENDO 2026 contribute significantly towards a deeper understanding of treating classic CAH, particularly for patients with 11β-hydroxylase deficiency. The implications of these findings are likely to inspire further investigation into therapeutic options for CAH, promising hope for numerous patients and healthcare providers navigating this complex landscape.